DK0697875T3 - Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme - Google Patents

Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme

Info

Publication number
DK0697875T3
DK0697875T3 DK94917384T DK94917384T DK0697875T3 DK 0697875 T3 DK0697875 T3 DK 0697875T3 DK 94917384 T DK94917384 T DK 94917384T DK 94917384 T DK94917384 T DK 94917384T DK 0697875 T3 DK0697875 T3 DK 0697875T3
Authority
DK
Denmark
Prior art keywords
cells
cancer
viral diseases
modified
treatment
Prior art date
Application number
DK94917384T
Other languages
English (en)
Inventor
Daniela Santoli
Giovanni Rovera
Alessandra Cesano
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Application granted granted Critical
Publication of DK0697875T3 publication Critical patent/DK0697875T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1203—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94917384T 1993-05-14 1994-05-12 Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme DK0697875T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6318893A 1993-05-14 1993-05-14
PCT/US1994/005374 WO1994026284A1 (en) 1993-05-14 1994-05-12 Use of modified tall-104 cells to treat cancer and viral diseases

Publications (1)

Publication Number Publication Date
DK0697875T3 true DK0697875T3 (da) 2002-04-29

Family

ID=22047549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94917384T DK0697875T3 (da) 1993-05-14 1994-05-12 Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme

Country Status (10)

Country Link
EP (1) EP0697875B1 (da)
JP (1) JP3541950B2 (da)
AT (1) ATE211915T1 (da)
AU (1) AU694430B2 (da)
CA (1) CA2162732C (da)
DE (1) DE69429657T2 (da)
DK (1) DK0697875T3 (da)
ES (1) ES2171169T3 (da)
PT (1) PT697875E (da)
WO (1) WO1994026284A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022538A (en) * 1995-06-06 2000-02-08 The Wistar Institute Of Anatomy And Biology Method of treating malignancies
US5800539A (en) * 1995-11-08 1998-09-01 Emory University Method of allogeneic hematopoietic stem cell transplantation without graft failure or graft vs. host disease
US6213127B1 (en) 1996-07-29 2001-04-10 Emory University Methods for treating cancer using allogeneic lymphocytes without graft vs host disease activity
WO1998049268A1 (en) 1997-04-30 1998-11-05 Hans Klingemann Natural killer cell lines and methods of use
WO2000050569A1 (en) * 1999-02-24 2000-08-31 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
WO2002066619A1 (en) * 2001-02-16 2002-08-29 The Wistar Institute Of Anatomy And Biology Methods of treating inflammation, particularly diabetes
ITMI20022118A1 (it) * 2002-10-04 2004-04-05 Abiogen Pharma Spa Procedimento per la coltura su larga scala di t-linfociti in un sistema omogeneo.

Also Published As

Publication number Publication date
DE69429657T2 (de) 2002-09-12
PT697875E (pt) 2002-07-31
AU694430B2 (en) 1998-07-23
AU6912694A (en) 1994-12-12
JPH08510131A (ja) 1996-10-29
EP0697875B1 (en) 2002-01-16
ATE211915T1 (de) 2002-02-15
WO1994026284A1 (en) 1994-11-24
JP3541950B2 (ja) 2004-07-14
CA2162732A1 (en) 1994-11-24
CA2162732C (en) 2007-01-09
EP0697875A4 (en) 1997-06-04
DE69429657D1 (de) 2002-02-21
EP0697875A1 (en) 1996-02-28
ES2171169T3 (es) 2002-09-01

Similar Documents

Publication Publication Date Title
EP1017797A4 (en) NON-ORIGINATING PRIMATE LENTIVIRUS VECTORS AND PACKAGING SYSTEMS
MY121548A (en) Compounds and methods for the treatment of cancer
EP1059929A4 (en) ISOLATED CURRENT CELLS FOR USE IN THE TREATMENT OF DISEASES OF THE CENTRAL VENEER SYSTEM
ATE199741T1 (de) Gentherapeutische behandlung von tumoren mit einem endothelzellspezifischen, zellzyklusabhängigen wirkstoff
ATE87214T1 (de) Verwendung katabolischer enzyme zur herstellung eines medikaments zum bekaempfen der erworbenen immunschwaeche (aids) und deren vorstadien (las, arc).
HK1028935A1 (en) Treatment of neoplasms with interferon-sernsitive,clonal viruses
YU29099A (sh) Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
DE69434244D1 (de) Verbesserte krebstherapie
DE3376295D1 (en) Pharmaceutical composition containing adenosine derivatives for use in treating tumours
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
DK0697875T3 (da) Anvendelse af modificerede TALL-104 celler til behandling af cancer og virale sygdomme
ATE404226T1 (de) Zusammensetzung enthaltend auf festen teilchen immobilisierte radioisotopen, sowie deren verwendung in der brachytherapie
BRPI0418157A (pt) terapêutica de tumores alogênicos
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
PT951553E (pt) Proteinas de e4 de adenovirus para unducao de morte celular
NZ319365A (en) Allogeneic mononuclear phagocytes introduced near injured site are used to promote axonal regeneration in the cns
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
GR3015824T3 (en) Biologically active compounds from blue-green algae.
DE3374066D1 (en) N-acyl derivatives of peptides, their manufacture and use in combating diseases and means therefor
WO2005007109A3 (en) Methods and compositions for cancer therapy using a novel adenovirus
Hunt et al. Accelerated myelopoietic recovery in irradiated mice treated with photofrin®
ATE381345T1 (de) Alpha-emittierende konstrukte sowie deren verwendung
Spikalovas et al. Brachytherapy for the malignant tumours of vagina
Scarpati et al. Total body irradiation before allogeneic and autologous bone marrow transplantation: a ten year Genoa experience